Skip to main content
. 2021 Oct 1;28(6):925–932. doi: 10.1177/13524585211047223

Figure 3.

Figure 3.

Median IgG titers by visit and initial randomized treatment group in AQP4–IgG–seropositive participants receiving inebilizumab for ⩾4 years.

AQP4: aquaporin-4; Ig: immunoglobulin; OLE: open-label extension; RCP: randomized controlled period.

The RCP is indicated in gray. All participants received inebilizumab during the OLE. Bars represent the median absolute deviation.